Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
TARS 
Tarsus Pharmaceuticals Inc (TARS)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/17/2025: TARS (4-star) is a STRONG-BUY. BUY since 92 days. Simulated Profits (62.53%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $87.5
1 Year Target Price $87.5
| 6 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 310.17% | Avg. Invested days 56 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.30B USD | Price to earnings Ratio - | 1Y Target Price 87.5 |
Price to earnings Ratio - | 1Y Target Price 87.5 | ||
Volume (30-day avg) 8 | Beta 0.75 | 52 Weeks Range 38.51 - 85.25 | Updated Date 12/18/2025 |
52 Weeks Range 38.51 - 85.25 | Updated Date 12/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -22.17% | Operating Margin (TTM) -12.24% |
Management Effectiveness
Return on Assets (TTM) -12% | Return on Equity (TTM) -28.35% |
Valuation
Trailing PE - | Forward PE 131.58 | Enterprise Value 2976035806 | Price to Sales(TTM) 9.02 |
Enterprise Value 2976035806 | Price to Sales(TTM) 9.02 | ||
Enterprise Value to Revenue 8.13 | Enterprise Value to EBITDA -3.23 | Shares Outstanding 42449105 | Shares Floating 30220367 |
Shares Outstanding 42449105 | Shares Floating 30220367 | ||
Percent Insiders 3.04 | Percent Institutions 110.97 |
About Tarsus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2020-10-16 | Co-Founder, President, CEO & Chairman Dr. Bobak R. Azamian M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 323 | Website https://www.tarsusrx.com |
Full time employees 323 | Website https://www.tarsusrx.com | ||
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.